|
|
|
|
| Don't miss the next Cell & Gene Live discussion on how CAR-T manufacturing has advanced recently and where it's going. Host Tyler Menichiello welcomes CTMC's Jason Bock, Ph.D., Cartesian Therapeutics' Emily English, Ph.D., and former FDA-turned Dark Horse consultant and CMC Expert, Tal Salz, Ph.D., for this digital event happening Tuesday, August 27, at 11 AM ET. Registration is free thanks to the support of CPC. |
|
|
|
|
By Tyler Menichiello, contributing editor | Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies. |
|
|
|
|
In one of our most active Cell & Gene Live audience Q&As to date, Will Junker and Nick Siciliano responded to several audience questions ranging in scope from reducing environmental control requirements with respect to total COGs for cell therapy manufacturing to the technologies that benefit in closing of processes. |
|
|
|
| A Focus On Cell Therapy: CAR-T, CAR-NK, And Beyond | Article | By Tae Whan Kim, GC Cell | As the landscape of CAR T-cell therapies evolves, these treatments are becoming more precise in targeting cancer cells and overcoming production challenges, and are poised to revolutionize oncology. |
|
|
| Optimizing And De-risking Your mRNA Product Manufacture | Article | Novartis Contract Manufacturing | mRNA therapy and vaccine manufacturing can become complex and challenging when working with multiple CMOs. Partnering with an end-to-end CMO is key to overcoming these challenges. |
|
|
|
| Analytical Considerations For mRNA-Based Therapies | Article | By Mark Rogers, Ph.D., SGS | Uncover why leveraging strong scientific expertise and comprehensive testing techniques will be vital in expediting development and upholding the integrity of these life-saving treatments. |
|
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
